Classical neurotransmitters and neuropeptides involved in generalized epilepsy in a multi-neurotransmitter system: How to improve the antiepileptic effect?

Epilepsy and Behavior

Volumn 71, Issue , 2017, Pages 124-129

  Werner, Felix Martin ^a,b   Coveñas, Rafael ^b  

^a Höhere Berufsfachschule für Altenpflege und Ergotherapie der Euro Akademie Pößneck   (Germany)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Antiepileptic drugs; Dopamine; GABA; Generalized epilepsy; Glutamate; Neural network; Serotonin; Topiramate

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADENOSINE; ADENOSINE A2 RECEPTOR; ANTICONVULSIVE AGENT; BUNGAROTOXIN RECEPTOR; CARBAMAZEPINE; CORTICOTROPIN; DOPAMINE; DYNORPHIN; ETHOSUXIMIDE; GALANIN; GLUTAMIC ACID; LAMOTRIGINE; LEVETIRACETAM; METABOTROPIC RECEPTOR 5; NEUROPEPTIDE; NEUROPEPTIDE Y; NEUROTRANSMITTER; NORADRENALIN; PHENYTOIN; RUFINAMIDE; SEROTONIN; SEROTONIN 7 RECEPTOR; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ANTICONVULSANT ACTIVITY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; BRAIN CORTEX; CONNECTOME; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MECHANISM; GABAERGIC SYSTEM; GENERALIZED EPILEPSY; HAMSTER MODEL; HIPPOCAMPUS; HUMAN; LENNOX GASTAUT SYNDROME; NERVE CELL NETWORK; NONHUMAN; SEROTONINERGIC NERVE CELL; THALAMUS; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; EPILEPSY, GENERALIZED; GABAERGIC NEURONS; HIPPOCAMPUS; HUMANS; NERVE NET; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; THALAMUS; TREATMENT OUTCOME;

EID: 84925813918     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.01.038     Document Type: Article

References (42)

1. Mumenthaler, M., Matte, H., Epilepsien und andere Erkrankungen mit anfallsartigen Erscheinungen und/oder Bewusstseinsstörungen. Mumentaler, M., Matte, H., (eds.) Neurologie, 2008, Thieme, Stuttgart, 436–450.
2. Werner, F.-M., Coveñas, R., Behandlung des Status epilepticus anhand eines neuronalen Netzwerkes. ANIM-Abstract CD, 2012, P326 [www.anim2012.de].
3. Badaway, R.A.B., Harvey, A.S., Macdonald, R.A.L., Cortical hyperexcitability and epileptogenesis: understanding the mechanisms of epilepsy. Part 1. J Clin Neurosci 16 (2009), 355–365.
4. Werner, F.-M., Coveñas, R., Classical neurotransmitters and neuropeptides involved in generalized epilepsy: a focus on antiepileptic drugs. Curr Med Chem 18 (2011), 4933–4948.
5. Sperk, G., Hamilton, T., Colmers, W.F., Neuropeptide Y in the dentate gyrus. Prog Brain Res 163 (2007), 285–297.
6. Fuentes-Santamarina, V., Alvarado, J.C., Herranz, A.S., García-Atarés, N., López, D.E., Decreased levels of GABA in the inferior colliculus of the epilepsy-prone hamster (GPG/Vall). Epilepsy Res 79 (2013), 224–227.
7. Barrera-Bailón, B., Oliveira, J.A., López, D.E., Muñoz, L.J., Garcia-Caraisco, N., Sancho, C., Pharmacological and neuroethiological studies of three antiepileptic drugs in the Genetic Audiogenic Seizure Hamster (GASH:Sal). Epilepsy Behav 28 (2013), 413–425.
8. Ketzef, M., Kahn, J., Weissberg, I., Becker, A.J., Friedman, A., Gitler, D., Compensatory network alterations upon onset of epilepsy in synapsin triple knock-out mice. Neuroscience 189 (2011), 108–122.
9. Dahlin, M., Mansson, J.E., Amark, P., CSF levels of dopamine and serotonin, but not norepinephrine, metabolites are influenced by the ketogenic diet in children with epilepsy. Epilepsy Res 99 (2012), 132–138.
10. Werner, F.-M., Coveñas, R., Klassische Neurotransmitter und Therapiemöglichkeiten bei generalisierten Epilepsien. ANIM-Abstract CD, 2009, P63 [www.anim2009.de].
11. Butuzova, M.V., Kitchigina, V.E., Repeated blockade of GABAA receptors in the medial septal region induces epileptiform activity in the hippocampus. Neurosci Lett 434 (2008), 133–138.
12. Jacob, T.C., Moss, S.J., Jurd, R., GABAA receptor trafficking in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci 9 (2008), 331–343.
13. Bertram, E.H., Zhang, D., Williamson, J.M., Multiple roles of midline dorsal thalamic nuclei and spread of limbic seizures. Epilepsia 49 (2007), 256–268.
14. Mares, P., Tabashidze, N., Contradictory effects of GABA-B receptor agonists on cortical epileptic afterdischarges in immature rats. Brain Res Bull 75 (2008), 173–178.
15. Tang, F.R., Chen, P.M., Tang, Y.C., Tasi, M.C., Lee, W.L., Two-methyl-6-phenylethynyl-pyridine (MPEP), a metabotropic glutamate receptor 5 antagonist, with low dose of MK801 and diazepam: a novel approach for controlling status epilepticus. Neuropharmacology 53 (2007), 821–831.
16. Kanner, A.M., Mood disorders and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci 10 (2008), 39–45.
17. Jurgens, C.W., Boese, S.J., King, J.D., Pyle, S.J., Porter, J.E., Doze, V.A., Adrenergic receptor modulation of hippocampal CA3 network activity. Epilepsy Res 66 (2005), 117–128.
18. Birioukova, L.M., Medzyanovskaya, I.S., Lensu, S., Tuomisto, L., van Luijtelaar, G., Distribution of D1-like and D2-like dopamine receptors in the brain of genetic WAG/Rij rats. Epilepsy Res 63 (2005), 89–96.
19. Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., Michotte, Y., Anticonvulsant action of GBR-12,909 and citalopram against acute experimentally induced limbic seizures. Neuropharmacology 47 (2004), 1053–1061.
20. Thomé-Souza, M.S., Kuczynski, E., Valente, K.D., Sertraline and fluoxetine: safe treatment for children and adolescents with epilepsy and depression. Epilepsy Behav 10 (2007), 417–425.
21. Pericic, D., Svob-Strae, D., The role of 5-HT7 receptors in the control of seizures. Brain Res 1141 (2007), 48–55.
22. Haug, K.H., Myhrer, T., Fonnum, F., The combination of donepezil and procyclidine protects against soman-induced seizures in rats. Toxicol Appl Pharmacol 220 (2007), 156–163.
23. Feuerbach, D., Ingenhoehl, K., Olpe, H.R., Vassout, A., Gentsch, C., Chaperon, F., et al. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56 (2008), 254–263.
24. Cunha, R.A., Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signal 1 (2005), 111–134.
25. Werner, F.-M., Coveñas, R., Classical neurotransmitters and neuropeptides in Alzheimer and Parkinson diseases. Coveñas, R., Mangas, A., Nárvaez, J.A., (eds.) Focus on neuropeptide research, 2007, Transworld Research Network, Trivandrum, 299–399.
26. Werner, F.-M., Coveñas, R., Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 120 (2010), 455–470.
27. Werner, F.-M., Coveñas, R., Classical neurotransmitters and neuropeptides involved in schizophrenia: how to choose the appropriate antipsychotic drug?. Curr Drug Ther 8 (2013), 132–143.
28. Zhang, S.W., Liu, Y.X., Changes of serum adrenocorticotropic hormone and cortisol levels during sleep seizures. Neurosci Bull 24 (2008), 84–88.
29. Loacker, S., Sayyah, M., Wittmann, W., Herzog, H., Schwarzer, C., Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130 (2007), 1017–1028.
30. Lerner, J.T., Sankar, R., Mazarati, A.M., Galanin and epilepsy. Cell Mol Life Sci 65 (2008), 1864–1871.
31. Meurs, A., Clinckers, R., Ebinger, G., Michotte, Y., Smolders, I., Clinical potential of neuropeptide Y receptor ligands in the treatment of epilepsy. Curr Top Med Chem 7 (2007), 1660–1674.
32. Werner, F.-M., Coveñas, R., Mechanism of action of newer antiepileptic drugs: how to improve the antiepileptic effect?. DGfE-Abstract CD, 2014, P18 [www.epilepsie2014.de].
33. + channel inhibitors: a simulation and experimental study. PloS Compact Biol, 6, 2010, e10000818.
34. + channels. Neuropharmacology 56 (2009), 499–506.
35. Ramsay, E., Faught, E., Krumholz, A., Naritoku, D., Privitera, M., Scharzman, L., et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 51 (2010), 1970–1977.
36. Kus, K., Burda, K., Nowakowska, E., Czzubak, A., Metelska, J., Lancucki, M., et al. Effect of valproic acid and environmental enrichment on behavioral functions in rats. Arzneimittelforschung 60 (2010), 471–478.
37. Glauser, T.A., Cnaan, A., Shinnar, S., Hirtz, D.G., Dlugos, D., Masur, D., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 362 (2010), 790–799.
38. Boido, D., Farisello, P., Cesca, F., Ferrea, E., Valtorta, F., Benfenati, F., et al. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam. Neuroscience 171 (2010), 268–283.
39. Kluger, G., Kurlemann, G., Haberlandt, E., Ernst, J.P., Runge, U., Schneider, F., et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 14 (2009), 491–495.
40. Rawls, S.M., Thomas, T., Adeola, M., Patil, T., Raymondi, N., Poles, A., et al. Topiramate antagonizes NMDA- and AMPA-induced seizure-like activity in planarians. Pharmacol Biochem Behav 93 (2009), 363–367.
41. Sonsalla, P.K., Wong, L.Y., Winnik, B., Buckley, B., The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP activity in mice: clinical relevance. Exp Neurol 221 (2010), 329–334.
42. Grover, N.D., Limaye, R.P., Gokhale, D.V., Patil, D.R., Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian J Pharmacol 45 (2013), 547–555.